Form 8-K - Current report:
SEC Accession No. 0001104659-25-068099
Filing Date
2025-07-15
Accepted
2025-07-15 16:15:51
Documents
12
Period of Report
2025-07-11
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2520941d1_8k.htm   iXBRL 8-K 35465
  Complete submission text file 0001104659-25-068099.txt   201007

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ymab-20250711.xsd EX-101.SCH 3005
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ymab-20250711_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ymab-20250711_pre.xml EX-101.PRE 22352
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2520941d1_8k_htm.xml XML 3684
Mailing Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540 646-885-8505
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 251124969
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)